Patents by Inventor Martin Emanuele

Martin Emanuele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150093368
    Abstract: The present invention provides methods for preventing the adverse effects of transfusing a patient with blood or blood products compromised by storage lesion. The methods include administering to a patient a pharmaceutical composition comprising an effective amount of a polyoxyethylene/polyoxypropylene copolymer and a pharmaceutically acceptable carrier. The safety and effectiveness of transfusing blood with storage lesion can be increased using the methods of the invention.
    Type: Application
    Filed: November 25, 2014
    Publication date: April 2, 2015
    Applicant: Mast Therapeutics, Inc.
    Inventor: R. Martin Emanuele
  • Publication number: 20110212047
    Abstract: Methods are provided for the treatment of chronic microvascular diseases characterized by inflammation, such as age-related macular degeneration, by administering a polyoxyethylene/polyoxypropylene copolymer. Although a single dose can be effective, multiple treatments can be administered to achieve an optimal and sustained effect. Preferably, a single administration followed by repeated weekly administration of the pharmaceutical composition, but not continuous infusion, achieves a desired effect. Methods of diagnosis and characterization of chronic microvascular diseases using the copolymer are also provided.
    Type: Application
    Filed: August 11, 2008
    Publication date: September 1, 2011
    Applicant: Synth Rx, Inc.
    Inventors: Robert L. Hunter, Martin Emanuele
  • Patent number: 7202225
    Abstract: The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: April 10, 2007
    Inventors: R. Martin Emanuele, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
  • Patent number: 7045576
    Abstract: The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymers compositions and compounds. The compositions comprise block copolymers that are useful in gene therapy methods.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: May 16, 2006
    Assignee: Cytrx Corporation
    Inventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuele, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey, III
  • Patent number: 6933286
    Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula: wherein “b” represents a number such that the molecular weight of the hydrophobe (C3H6O)b is between approximately 750 and 20,000 Daltons and “a” represents a number such that the percentage of hydrophile (C2H4O)a is between approximately 1% and 90% of the weight of the block copolymer.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: August 23, 2005
    Inventors: R. Martin Emanuele, Mark Newman, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
  • Publication number: 20040248833
    Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences.
    Type: Application
    Filed: August 2, 2004
    Publication date: December 9, 2004
    Inventors: R Martin Emanuele, Konstantin G Kousoulas, Hameedsulthan S Allaudeen, Mark Newman
  • Patent number: 6747064
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: June 8, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Publication number: 20020197599
    Abstract: The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.
    Type: Application
    Filed: April 2, 2002
    Publication date: December 26, 2002
    Inventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuele, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey
  • Publication number: 20020183398
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Application
    Filed: December 14, 2001
    Publication date: December 5, 2002
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Publication number: 20020128218
    Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences.
    Type: Application
    Filed: August 14, 2001
    Publication date: September 12, 2002
    Inventors: R. Martin Emanuele, Mark Newman, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
  • Publication number: 20020123476
    Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences.
    Type: Application
    Filed: July 31, 2001
    Publication date: September 5, 2002
    Inventors: R. Martin Emanuele, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
  • Patent number: 6416947
    Abstract: The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: July 9, 2002
    Assignee: CytRx Corporation
    Inventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuele, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey, III
  • Patent number: 6359014
    Abstract: The present invention comprises preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: March 19, 2002
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 6149922
    Abstract: The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: November 21, 2000
    Assignee: CytRx Corporation
    Inventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuele, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey, III
  • Patent number: 6086899
    Abstract: The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: July 11, 2000
    Assignee: CytRx Corporation
    Inventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuele, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey, III
  • Patent number: 5990241
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: November 23, 1999
    Assignee: CytRx, Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5811088
    Abstract: In accordance with the present invention, a composition and method is provided that is effective in treating infections caused by microorganisms including, but not limited to, bacteria, viruses, and fungi. The present invention is effective in inhibiting the growth of bacteria such as Mycobacterium species including, but not limited to, Mycobacterium avium-intracellulare complex and M. tuberculosis. The present invention comprises a surface active copolymer, preferably an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 1200 to 15,000, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.4 O) constitutes approximately 1% to 50% by weight of the compound.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 22, 1998
    Assignee: Emory University
    Inventors: Robert L. Hunter, R. Martin Emanuele, Hameedsulthan S. Allaudeen
  • Patent number: RE37285
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: July 17, 2001
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE38558
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: July 20, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE36665
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: April 18, 2000
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth